This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Johnson & Johnson said Tuesday that it plans to spin out its orthopedics business, creating a standalone company that would compete with firms like Stryker and Zimmer Biomet. The healthcare giant said the decision is intended to focus its medtech unit on higher-growth and higher-margin markets. The spinout, which will be called DePuy Synthes, is expected to happen in ...

We recently published Wall Street Analysts Like These 10 Stocks. Johnson & Johnson (NYSE:JNJ) is one of the stocks analysts were recently talking about. Josh Brown, CEO of Ritholtz Wealth Management, explained in a latest program on CNBC why he likes Johnson & Johnson (NYSE:JNJ). Brown said the company’s upcoming quarterly report next month could be a big catalyst. “The general idea is that if and when a stock breaks out from a typical range that it’s been stuck in, in this case like 5 years, the move co ...